Table 1

Baseline Characteristics of the Study Population

Treatment Armp Value
LAA Closure
(n = 732)
Long-Term Warfarin
(n = 382)
Age, yrs72.5 ± 8.473.5 ± 8.60.09
Age >65 yrs616 (84.2)329 (86.1)0.38
Male508 (69.4)274 (71.7)0.45
Hypertension653 (89.2)354 (92.7)0.07
Diabetes mellitus204 (27.9)113 (29.6)0.58
Previous myocardial infarction105 (14.3)77 (20.2)0.02
Previous stroke104 (14.2)61 (16.0)0.43
Previous major bleeding96 (13.1)52 (13.6)0.82
CHADS22.3 ± 1.12.4 ± 1.20.06
CHA2DS2-VASc3.6 ± 1.43.8 ± 1.50.02
CHA2DS2-VASc ≥2692 (94.9)367 (96.8)0.17
Modified HAS-BLED1.9 ± 0.91.9 ± 1.0NS

Values are mean ± SD or n (%). Patients were randomized in a 2:1 fashion to either LAA closure or long-term warfarin. The modified HAS-BLED score provided zero points for liver disease and labile international normalized ratio.

CHADS2 = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke; CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–74 years, sex category; LAA = left atrial appendage; NS = not significant.